报价延迟最少15分钟:2026/03/10 00:52 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.53 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.72/6.50
|
|
企业价值
10.34B
|
| 资产负债 |
|
每股账面净值
2.89
|
| 现金流量 |
|
现金流量率
0.41
|
| 损益表 |
|
收益
6.22B
|
|
每股收益
23.63
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio. |
